undamentalytics Newsletter

Moran Sean F.: insider trades

Chief financial officer at Corbus Pharmaceuticals Holdings, Inc. 17 open-market purchases and no sales not made under a pre-set plan, reported from December 22, 2014 to March 14, 2019.

Would copying Moran Sean F.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 9 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on September 9, 2016 into $8,081 by November 2, 2026, −2.1% a year. The copy held shares only 35% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $14,700, +3.9% a year (the S&P 500 held throughout made $41,743, +15.2% a year). Beta against the index was 0.46. Twelve months after each report, the average purchase was −18.3% against the S&P 500 (median −17.8%), and 22% beat it. Measured from the trade date, the insider’s own timing, the average was −18.9%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201620182020202220242026 $41.7k$14.7k$8.1k
Copying Moran Sean F.S&P 500, same days investedS&P 500, held throughout $10,000 copying Moran Sean F.’s open-market purchases from September 9, 2016, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−2.1%
S&P 500, same days invested
+3.9% (held throughout +15.2%)
Time in shares
35%
Sharpe ratio (S&P 500)
0.11 (0.74)
Biggest drop (S&P 500)
−67% (−34%)
Market sensitivity (beta)
0.46
Purchases copied
9

Trade by trade

Moran Sean F.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 9 +0.1% −0.6% 44% 4 0.10 0.92 No reliable evidence
Purchases, 6 months after the report 9 −4.9% −15.6% 44% 4 −0.59 0.60 No reliable evidence
Purchases, 12 months after the report 9 −18.3% −17.8% 22% 4 −2.05 0.13 No reliable evidence
Purchases, 12 months after the trade 9 −18.9% −17.6% 22% 4 −1.74 0.18 No reliable evidence
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Corbus Pharmaceuticals Holdings, Inc. CRBP Chief Financial Officer170December 22, 2014March 14, 2019

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 14, 2019March 14, 2019 CRBP Purchase $10,005 −0.6%−35.2%−38.0%
May 15, 2018May 15, 2018 CRBP Purchase $23,080 −28.8%+6.2%+7.7%
March 14, 2018March 14, 2018 CRBP Purchase $20,460 −13.4%−5.5%−6.1%
November 13, 2017November 10, 2017 CRBP Purchase $10,560 +16.2%−17.8%−17.6%
August 11, 2017August 11, 2017 CRBP Purchase $14,775 +14.6%−37.1%−38.6%
May 12, 2017May 11, 2017 CRBP Purchase $20,262 −9.3%−17.3%−27.1%
March 13, 2017March 13, 2017 CRBP Purchase $19,200 −39.0%−44.6%−47.6%
December 2, 2016December 2, 2016 CRBP Purchase $10,800 +16.0%−20.8%−17.1%
September 8, 2016September 8, 2016 CRBP Purchase $157,696 +44.9%+7.7%+14.7%
August 26, 2016August 26, 2016 CRBP Purchase $70,168 not yetnot yetnot yet
August 18, 2016August 17, 2016 CRBP Purchase $494,032 not yetnot yetnot yet
May 19, 2016May 19, 2016 CRBP Purchase $64,582 not yetnot yetnot yet
May 18, 2016May 18, 2016 CRBP Purchase $71,700 not yetnot yetnot yet
September 16, 2015September 16, 2015 CRBP Purchase $10,600 not yetnot yetnot yet
September 15, 2015September 15, 2015 CRBP Purchase $10,700 not yetnot yetnot yet
June 9, 2015June 9, 2015 CRBP Purchase $19,500 not yetnot yetnot yet
December 22, 2014December 18, 2014 CRBP Purchase $63,168 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Moran Sean F. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.